According to FutureWise analysis, the market for Migraine Treatment in 2023 is US$ 2.83 billion and is expected to reach US$ 5.64 billion by 2031 at a CAGR of 9.02%.
Migraine is a debilitating neurological disorder characterized by recurring episodes of severe throbbing head pain that can last up to three days. These headaches are usually one-sided and can vary in duration from four hours to three days. Common symptoms accompanying the pain include nausea, increased sensitivity to sound (phonophobia), vomiting, increased sensitivity to light (photophobia), tingling or numbness in the extremities or legs, sweating, and diarrhea.
A significant rise in the number of migraine cases is one of the main factors driving the growth of the Migraine Treatment Market. Improved payment regulations for migraine therapies and the increasing demand for precision medications are also contributing to this market expansion. Additionally, there is a growing demand for electrical nerve-stimulation devices to treat migraines, alongside the anticipated approval of new classes of late-stage pipeline drugs that demonstrate higher clinical efficacy, such as calcitonin gene-related peptide (CGRP) monoclonal antibodies.
FutureWise Market Research has published a report that provides an insightful analysis of Migraine Treatment Market trends that are affecting the overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=14662%20&type=requestsample
Migraine Treatment Market Segmentation:
By Types
- Episodic
- Migraine with Aura
- Chronic
- Others
By Treatment
- Acute/Abortive Treatment
- Preventive/prophylactic Treatment
- Non-Pharmacological Therapies and Devices
By Route of Administration
- Oral
- Parenteral
By Product
- Prescription
- Over The Counter
By Distribution Channel
- Hospital-Based Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
By End-Users
- Hospitals
- Clinics
- Homecare
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Migraine Treatment Market:
- Pfizer Inc.
- Eli Lilly and Company
- Amgen Inc.
- GlaxoSmithKline plc.
- Novartis AG
- Bayer AG
- Allergan
- Abbott
- Allodynic Therapeutics, LLC
- AOBiome
- AstraZeneca
- Aurobindo Pharma USA
- Bausch Health Companies Inc.
- Biohaven Pharmaceuticals
- Catalent, Inc
- Dr. Reddy’s Laboratories Ltd.
- Impel Pharmaceuticals Inc.
- H. Lundbeck A/S
- Merck & Co., Inc
- Boehringer Ingelheim International GmbH
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=14662&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Migraine Treatment Market By Types, By Treatment, By Route of Administration, By Product, By Distribution Channel, By End-Users and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
